USANA Health (USJ) AI Stock Analysis
USANA Health
(Frankfurt:USJ)
No summary available
USANA Health (USJ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 264.40M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -11.9
- Beta (1Y)
- 0.69
- Revenue Growth
- -5.39%
- EPS Growth
- -162.53%
- Country
- Germany
- Employees
- 1,570
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
USANA Health Business Overview & Revenue Model
Company Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. Th...
USANA Health Earnings Call Summary
The call balanced clear strategic progress (strong balance sheet, stable core nutrition, successful new product launches, and retail expansion for Hiya and Rise) with meaningful near-term operational and financial headwinds (a $29M goodwill impairment for Hiya, a quarterly pre-tax loss with a $9M tax charge, lowered full-year outlook, Hiya DTC marketing pressures, and a Rise packaging disruption). Management emphasized long-term conviction and the ability to invest, but acknowledged near-term impacts to revenue, margins, and tax rates.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management lowered its fiscal 2026 outlook — citing a tougher direct‑to‑consumer digital marketing environment for Hiya and a packaging disruption at Rise Wellness — and now expects Hiya full‑year net sales to be lower than previously anticipated and near‑term net sales at Rise to be reduced; the quarter included a preliminary non‑cash goodwill impairment charge of $29.0 million related to Hiya and a $9.0 million income tax expense on a $19.0 million pre‑tax loss, management said the update reflects roughly a $30–40 million top‑line swing versus prior expectations with about $4–5 million of margin pressure, and they noted an elevated tax rate for the back half of the year despite a strong balance sheet of $169.0 million in cash, zero debt, $20.0 million of free cash flow this quarter, Hiya’s historical advertising spend of about $150.0 million, and Rise’s planned retail footprint of over 4,000 doors by year‑end.
USANA Health Risk Analysis
USANA Health disclosed 43 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksUSANA Health Peers Comparison
Overall Rating
HLF60Neutral
LFVN59Neutral
NATR59Neutral
FTLF52Neutral
NAII40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| HLF | 60Neutral | $1.37B | 8.16 | -32.15% | ― | 5.52% | -50.47% |
| LFVN | 59Neutral | $74.03M | 14.70 | 15.25% | 3.23% | -20.10% | -49.17% |
| NATR | 59Neutral | $215.55M | 12.01 | 11.00% | ― | 6.77% | 34.53% |
| FTLF | 52Neutral | $73.63M | 11.88 | 13.98% | ― | 60.61% | -22.94% |
| NAII | 40Underperform | $6.71M | -0.31 | -33.23% | ― | 9.08% | -52.59% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:USJ | USANA Health Sciences Inc | 12.30 | -5.60 | -31.28% | |
| HLF | Herbalife Ltd | 13.05 | 4.98 | 61.71% | |
| NAII | Natural Alternatives International | 1.07 | -1.66 | -60.81% | |
| NATR | Nature's Sunshine Products | 12.25 | -1.51 | -10.97% | |
| LFVN | LifeVantage Corp | 5.88 | -1.24 | -17.39% | |
| FTLF | Fitlife Brands | 7.84 | -11.47 | -59.40% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.